We exceeded our adjusted earnings per share expectations for the fourth quarter in a row delivering $1.98 adjusted earnings per share in the final quarter of 2021 and $8.40 adjusted earnings per share for the full year.
For the full year 2021, CVS Health grew adjusted revenue by 8.8% to $292 billion.
We delivered adjusted operating income of $17.3 billion, up 8.1% year over year.
And we increased adjusted earnings per share by 12%.
We generated strong cash flow from operations of nearly $18.3 billion for the full year, exceeding our most recent guidance of at least $13.5 billion.
At this early stage of the year, we are maintaining our full year 2022 adjusted earnings per share guidance of $8.10 to $8.30.
In healthcare benefits, we delivered 9.4% adjusted revenue growth for the full year 2021, driven by our performance in government services.
Total Medicare Advantage membership grew at 9.8% on a year-over-year basis, as we added over 265,000 new members in 2021 and exceeded our initial growth expectations.
Our full year medical benefit ratio of 85% was in line with our guidance expectations.
We grew total Medicare Advantage membership by 11.6% versus the prior year, reflecting increases in individual and group Medicare Advantage of over 15% and 6%, respectively, year over year.
This added nearly 295,000 net new members, while the overall PDP market continues to decline.
We expect to grow membership in the low single digits for the full year and maintained strong client retention of 96%.
For 2022, we forecast 7% to 9% revenue growth and 15% to 17% adjusted operating income growth.
Turning to pharmacy services, we delivered 7.8% revenue and 20.6% adjusted operating income growth in 2021.
For 2022, we achieved a client retention rate of over 98% and drove $8.8 billion of net new business revenue.
We are a leader in specialty pharmacy, delivering revenue growth of 12.3% for the fourth quarter and 9.3% for the full year versus prior period.
For pharmacy services in 2022, we expect 6% to 8% revenue growth and 7% to 9% adjusted operating income growth, as we create long-term value for our clients and our members.
We grew revenue 9.8% year over year to just over $100 billion, marking an important milestone in the history of this CVS Health business.
We delivered an exceptional 24% adjusted operating income growth in 2021.
Pharmacy sales and prescriptions filled both increased by nearly 9% year over year.
For the full year 2021, CVS Health administered more than 32 million COVID-19 tests and more than 59 million vaccines.
Over 35% of COVID-19 vaccines in 2021 were administered during the fourth quarter.
Front store sales growth was strong throughout 2021, up 8.4% versus the prior year.
We sold over 22 million OTC COVID-19 tests with approximately 70% of sales in the fourth quarter.
This now implies retail revenue to be plus or minus 1% versus prior year, and a low 20% decline in adjusted operating income growth.
CVS.com is one of the top health websites with over 2 billion visits in 2021, up nearly 55% over the prior year.
We now serve 40 million customers digitally, up approximately 10% in the last six months alone.
We made it easier to join our CarePass program reaching 5.6 million subscribers in the quarter, up more than 40% year over year.
Almost 80% of patients are already utilizing this capability.
Total fourth quarter adjusted revenues of 76.6 billion, increased by 10.6% year over year.
We reported adjusted operating income of 4.1 billion and adjusted earnings per share of $1.98, representing an increase of 40.8% and 52.3% versus prior year, respectively.
For full year 2021, we reported total adjusted revenues of 292.1 billion, an increase of 8.8% versus prior year, reflecting robust growth across all business segments.
We delivered adjusted operating income of 17.3 billion and adjusted earnings per share of $8.40, up approximately 8.1% and 12% year over year, respectively.
And we generated significant cash flow from operations of nearly 18.3 billion.
Fourth quarter adjusted revenue of 20.7 billion increased by 10.1% year over year, driven by membership growth in our government services business and lower COVID-19-related investments, slightly offset by the repeal of the health insurer fee.
Adjusted operating income of 510 million grew by over 230% year over year, driven by lower COVID-19 related investments and improved underlying performance, partially offset by higher COVID-related medical costs compared to prior year.
Our adjusted medical benefit ratio of 87% improved 130 basis points year over year, driven by lower COVID-19 related investments, partially offset by the repeal of the health insurer fee.
Days claims payable at the end of the quarter was 49 and was, as expected, lower than the third quarter and consistent with normal seasonal trends and historic levels.
In the pharmacy services segment, fourth quarter revenues of 39.3 billion increased by 8.2% year over year, driven by increased pharmacy claims volume, growth in specialty pharmacy, and brand inflation, partially offset by the impact of continued client price improvements.
Total pharmacy membership increased by approximately 400,000 lives sequentially, reflecting sustained growth in government programs.
Total pharmacy claims processed increased by 8.2% above prior year.
Adjusted operating income of $1.8 billion grew 16.8% year over year, driven by improved purchasing economics, reflecting the products and services of our group purchasing organization, and growth in specialty pharmacy.
Fourth quarter revenue of 27.1 billion was up by 12.7% year over year, representing an increase of 3 billion.
There are two main components to this increase: one, approximately 60% was driven by the administration of COVID-19 vaccines and testing; front store sales, including demand for over-the-counter COVID test kits and related treatment categories; as well as strong COVID-related prescription volume.
The remaining 40% was attributable to a combination of underlying sustained pharmacy growth and broad strength in front store sales trends, partially offset by continued pharmacy reimbursement pressure.
This strong revenue growth helped produce adjusted operating income of 2.5 billion.
This quarterly result was 38% above prior year and significantly exceeded our forecasts.
The increase in adjusted operating income was driven by a few key components: the administration of COVID-19 vaccines, underlying strength in pharmacy and front store sales, and a $106 million gain from an antitrust legal settlement, which were partially offset by the combined impacts of ongoing but stable reimbursement pressure, and business investments, including the minimum wage increase and store improvements.
Approximately 75% was driven by vaccines, largely third-dose boosters, which we previously expected to impact the first quarter of 2022.
And the remaining 25% was driven by the nationwide surge in demand for over-the-counter and diagnostic COVID-19 testing, combined with stronger underlying front store sales performance.
Our liquidity and capital position remained strong at the end of the fourth quarter with full year cash flow from operations of nearly 18.3 billion and nonrestricted cash of over 3.8 billion.
Through our proactive liability management transaction in December, we paid down 2.3 billion in long-term debt in the quarter, bringing the total long-term debt we have repaid since the close of the Aetna transaction to a net total of 21 billion.
In addition, we returned over 2.6 billion to shareholders through our quarterly dividends in 2021.
As Karen noted earlier, we are maintaining our full year adjusted earnings per share guidance range of $8.10 to $8.30.
This represents 2% to 5% growth versus our revised 2021, adjusted earnings per share baseline of $7.92.
First, recall that our 2021 baseline of $7.92 removes items we do not forecast, prior year's development, net of profits returned to customers and net realized capital gains.
Second, it is also important to note that the baseline now includes a net favorable component attributable to COVID-19, driven by vaccines and testing of approximately $0.30 per share.
In 2022, we expect vaccine volumes to decline approximately 70% to 80% and in-store diagnostic testing volumes to decline 40% to 50% compared to 2021.
Turning to items that are below adjusted operating income on our income statement, we expect our interest expense for 2022 to be approximately $2.3 billion.
Our expectation for the effective income tax rate is approximately 25.6%, consistent with 2021.
And we are updating our guidance range to $12 billion to $13 billion, reflecting the improved cash flow results for 2021.
Capital expenditures are expected to be in the range of $2.8 billion to $3 billion as we invest in technology and digital enhancements to improve the consumer experience, as well as our community locations.
